|
Environmental Rx Announces Iso-barrier
Receives Patent
FARMINGDALE, N.Y.--(BUSINESS WIRE)--Nov. 10, 2004--Environmental
Rx (EVRX)
announced today that the US Patent Office approved the patent
for the Iso-barrier portable decontamination unit; a system
for sterilization of objects designed especially for hospital
beds and instruments. The Iso-barrier was designed to control
infection by combating bacteria. It is ideal for use by hospitals
to totally decontaminate hospital beds between patients.
Today's patients are given antibiotics as part of a standard
discharge. This is a result of the extremely high incidence
of infections resulting from contamination by other patients.
The Iso-barrier will eliminate this need. By using the Iso-barrier
between patients, the hospital can completely eliminate the
risk of contaminating the next patient. This is consistent
with EVRX's goal to step down medication for all patients.
EVRX's trained personnel can completely decontaminate a hospital
room in 30 minutes. A technician can move the Iso-barrier
from room to room as needed.
Environmental Rx is a multi faceted company that encompasses
health related services, indoor air quality, mold testing
and remediation, products and information technology. The
company is organized around indoor air quality, pollutant
pathways and the methodology to overcome allergic, pathogenic
and carcinogenic disease related to microorganisms. Each division
is serviced at the EVRX clinics springing up nationwide. EVRX
currently operates in Conroe, Texas and Long Island, N.Y.
Except for historical information contained herein, the statements
in this release are forward-looking statements that are made
pursuant to the safe harbor provision of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements
involve known and unknown risks and uncertainties that may
cause the companies' actual results in future periods to differ
materially from forecasted results. Such risks and uncertainties
include, but are not limited to, market conditions, competitive
factors, the ability to successfully complete additional financings
and other risks.
BACK TO INVESTOR RELATIONS
|
